Search company, investor...

Founded Year

2009

Stage

IPO | IPO

Total Raised

$33.2M

Date of IPO

12/17/2019

About Syntekabio

Syntekabio is a genomic big data and AI-driven drug discovery & development company. The company uses its computational biology technologies for drug candidate discovery. It also specializes in co-developing drug response biomarkers of existing drug candidates, which allows improvement of the likelihood of successful clinical trials, biomarker-driven indication expansion, and enhanced understanding of the drug's mechanism of action.

Headquarters Location

Migun Techno World, Building 2-B, Room 512 187, Techno 2-ro, Yuseong-gu

Daejeon, 34025,

South Korea

+82 070-7663-0958

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Syntekabio's Products & Differentiators

    DeepMatcher®

    Physics- and deep learning-based virtual screening solution

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Expert Collections containing Syntekabio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Syntekabio is included in 2 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

10,948 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

D

Digital Health

10,563 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Syntekabio Patents

Syntekabio has filed 7 patents.

The 3 most popular patent topics include:

  • Genetics
  • Learning methods
  • Machine learning
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/18/2021

1/4/2022

Betacoronaviruses, Animal virology, Viral respiratory tract infections, Animal viral diseases, Zoonoses

Grant

Application Date

3/18/2021

Grant Date

1/4/2022

Title

Related Topics

Betacoronaviruses, Animal virology, Viral respiratory tract infections, Animal viral diseases, Zoonoses

Status

Grant

Latest Syntekabio News

POLARISqb and Syntekabio sign MOU for Collaborative AI and Quantum-powered Drug Development Service

Aug 31, 2023

Durham, NC | August 31, 2023 09:00 AM Eastern Daylight Time POLARISqb, the first company in the world to develop a drug discovery engine that utilizes the optimization power of quantum computing, announced that it has signed an MOU with Syntekabio (KOSDAQ: 226330), an Artificial Intelligence (AI) based drug development company. The partnership, which will combine the companies’ vanguard drug research platforms, will provide a collaborative drug development service as well as develop new molecular leads. Through this business agreement, the two companies will discover active compounds with their respective AI and Quantum Computing platforms. Using these technologies, they will search for candidates with high druggability potential and offer these candidates to customers seeking novel molecular leads. POLARISqb is a quantum computing-based drug development company in Durham, North Carolina. As a leader in applying quantum computing in the world of drug discovery, the company has shortened the timelines for finding novel drug-like leads by orders of magnitude. In addition, POLARISqb has recently developed Quantum-Aided Drug Design (QuADD), a platform for generating new drug candidates using quantum annealing from exceptionally large molecular libraries. Using the increased optimization power of today’s quantum computers, this process can be accomplished in days rather than months. In this partnership they will leverage this optimization potential of quantum annealing computers, allowing the company to search a chemical space of 1030 potential molecules, a space many times larger than other computational chemistry platforms. Based on its own cloud supercomputing infrastructure, Syntekabio prepares big genomic data and AI drug platform services for implementation throughout the entire life cycle of novel drug development processes. Their platform includes services from the discovery of active compounds to the development of pre-clinical stage drug candidates (called DDC Service: DeepMatcher® Drug Candidate Service), as well as genomic biomarker discovery and detection services. Syntekabio plans to diversify lead candidates by applying POLARISqb's QuADD platform in the lead generation stage of DDC service. In addition, the two companies plan to jointly market their offering to global markets with specific emphasis on the US, Europe, and Asia. Combining the advantages of POLARISqb's quantum-based system and Syntekabio's AI discovery platform enhances precision medicine. This partnership seeks to help develop treatments to address various conditions and diseases that affect millions around the globe. Shahar Keinan, co-founder and CEO of POLARISqb, said, “QuADD is a quantum computing-based platform that is relevant to the pharma global market, representing a commercialized quantum product in the field of new drug design.” She added, "We expect to be able to find lead candidates quickly and efficiently in this partnership by providing new drug development services using Syntekabio's cloud supercomputer infrastructure and genome-based AI platform." Jongsun Jung, CEO of Syntekabio, said, "We are delighted that Syntekabio's DeepMatcher® and POLARISqb's QuADD can cooperate to provide a drug candidate discovery service. It will be of great help in expanding global business opportunities as we work together.” For more information about POLARISqb and its offering, please visit:

Syntekabio Frequently Asked Questions (FAQ)

  • When was Syntekabio founded?

    Syntekabio was founded in 2009.

  • Where is Syntekabio's headquarters?

    Syntekabio's headquarters is located at Migun Techno World, Building 2-B, Room 512, Daejeon.

  • What is Syntekabio's latest funding round?

    Syntekabio's latest funding round is IPO.

  • How much did Syntekabio raise?

    Syntekabio raised a total of $33.2M.

  • Who are the investors of Syntekabio?

    Investors of Syntekabio include Altos Ventures, Korea Asset Investment Securities Co., ASAM Asset Management, HB Advisors, Must Asset Management and 13 more.

  • Who are Syntekabio's competitors?

    Competitors of Syntekabio include Acellera.

  • What products does Syntekabio offer?

    Syntekabio's products include DeepMatcher® and 2 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Syntekabio to Competitors

C
Cloud Pharmaceuticals

Cloud Pharmaceuticals, formerly TeraDiscoveries, is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for partners.

B
BioSolveIT

BioSolveIT visualizes drug discovery. Its software enables every chemist to advance their research. Perceptive visualization helps the users to understand computational results at a glance.

PharmEnable Logo
PharmEnable

PharmEnable is a drug discovery company that uses a combination of medicinal chemistry and AI computational approaches to design small-molecule drugs. Its platform identifies novel active chemical starting points against biological targets, assisting the medical community to develop medicines such as novel antibacterial agents or potential cancer treatments. The company was founded in 2016 and is based in Cambridge, U.K.

Redesign Science Logo
Redesign Science

Redesign Science is a computational chemistry company that engages in early-stage, small molecule drug discovery. The company efficiently simulates protein targets at the atomic level to reveal hidden, subtle drug opportunities that fall outside the capability, and scope of alternative computational models.

P
PharmCADD

PharmCADD develops Pharmulator, a computer-aided drug discovery and development platform. The platform utilizes computational science methodologies, advanced machine learning technologies, and molecular dynamics. It was founded in 2019 and is based in Busan, South Korea.

M
Modulus Discovery

Modulus Discovery operates as a preclinical-stage technology-driven drug discovery company. It leverages the synthesis of computational intelligence, biological inspiration, and global integration. It focuses on the rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its computational drug discovery expertise and biology insights. The company was founded in 2016 and is based in Tokyo, Japan.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.